Mylan Takes Issue With FDA Over 'Major' CRL For Advair Generic
Executive Summary
FDA's complete response letter to Mylan's ANDA for a generic version of Advair was deemed a "major" CRL, likely delaying a launch into 2018.
You may also be interested in...
Mylan Insists Complex Generics Strategy Is Poised To Deliver
With one high-profile approval in its pocket – a version of Teva's blockbuster Copaxone – Mylan's management believes its strategy of investing in complex generics and biosimilars will help the company navigate challenges in the US generic market.
Mylan Insists Complex Generics Strategy Is Poised To Deliver
With one high-profile approval in its pocket – a version of Teva's blockbuster Copaxone – Mylan's management believes its strategy of investing in complex generics and biosimilars will help the company navigate challenges in the US generic market.
Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard
FDA issued a complete response letter for Hikma's ANDA to market a generic version of GSK's Advair, the second application to be rejected by FDA.